A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin-Reference-Cited by-同舟云学术

A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin

Published:2021-01-19 Issue:5 Volume:23 Page:1092-1100
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yamasaki Nozomu¹,Tamura Yoshifumi¹²^ORCID,Kaga Hideyoshi¹,Sato Motonori¹,Kiya Mai¹,Kadowaki Satoshi¹,Suzuki Ruriko¹,Furukawa Yasuhiko¹,Sugimoto Daisuke¹,Funayama Takashi¹,Someya Yuki²,Kakehi Saori²,Nojiri Shuko³,Satoh Hiroaki¹,Kawamori Ryuzo¹²,Watada Hirotaka¹²⁴⁵^ORCID

Affiliation:

1. Department of Metabolism and Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan

2. Sportology Center Juntendo University Graduate School of Medicine Tokyo Japan

3. Department of Medical Technology Center Juntendo University Faculty of Medicine Tokyo Japan

4. Center for Therapeutic Innovations in Diabetes Juntendo University Graduate School of Medicine Tokyo Japan

5. Center for Identification of Diabetic Therapeutic Targets Juntendo University Graduate School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14312

Reference25 articles.

1. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus

2. Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

3. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes;Biomedicines;2021-09-03

2. Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?;Diabetes, Obesity and Metabolism;2021-05-28